Oncothyreon to Present Updated Data on ONT-380 for the Treatment of HER2-Positive Breast Cancer at the San Antonio Breast Cancer Symposium

On November 16, 2015 Oncothyreon Inc. (Nasdaq:ONTY), a clinical-stage biopharmaceutical company dedicated to the development of oncology products that can improve the lives and outcomes of patients, reported that data from the company’s ongoing trials of ONT-380, an orally active, reversible and selective small-molecule HER2 inhibitor being developed for the treatment of metastatic breast cancer, will be presented at the upcoming San Antonio Breast Cancer Symposium (SABCS) being held December 8-12, 2015 in San Antonio, TX (Press release, Oncothyreon, NOV 16, 2015, View Source [SID:1234508251]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are looking forward to presenting additional and updated clinical trial data on ONT-380 for the treatment of patients with HER2-positive breast cancer, including an analysis of patients that suffer from central nervous system (CNS) metastases, at SABCS," said Robert L. Kirkman, M.D., President and CEO of Oncothyreon. "CNS metastases impact up to 50 percent of women with HER2-positive metastatic breast cancer and represent a major unmet medical need. ONT-380 is an exciting molecule that has the potential to provide a much needed treatment option for this patient population."

The SABCS presentation details are as follows:

A phase 1b study of ONT 380, an oral HER2-specific inhibitor, combined with ado trastuzumab emtansine (T DM1), in HER2+ metastatic breast cancer (MBC)

First Author: Cristiano Ferrario, Segal Cancer Centre, Jewish General Hospital, Montreal, QC
Date/Time: Friday, December 11, 2015 at 7:30-9:00 a.m. CT
Session: Poster Session 4: Treatment: HER2-Targeted Therapy
Abstract P4-14-20

ONT-380 in the treatment of HER2+ breast cancer central nervous system (CNS) metastases (mets)

First Author: Rashmi Krishna Murthy, MD Anderson Cancer Center, Houston, TX
Date/Time: Friday, December 11, 2015 at 7:30-9:00 a.m. CT
Session: Poster Session 4: Treatment: HER2-Targeted Therapy
Abstract P4-14-19